James Lillie is the Chief Scientific Officer at MapLight Therapeutics. He has more than 25 years of experience driving preclinical research and development across diverse therapeutic areas and indications. Previously, he served as the Chief Scientific Officer at OvaScience. As Vice President of In Vitro Biology at Sanofi Genzyme, he was responsible for developing a scientific strategy to create a high-value portfolio of treatments for rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug (IND) applications. Dr. Lillie holds a doctorate from Harvard University in biochemistry.